N-terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Concentrations in Hemodialysis Patients: Prognostic Value of Baseline and Follow-up Measurements

Nephrology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Clinical Chemistry (Impact Factor: 7.91). 07/2008; 54(8):1339-48. DOI: 10.1373/clinchem.2007.101691
Source: PubMed


Increased N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations are associated with increased cardiovascular mortality in chronic hemodialysis patients. Previous studies focused on prevalent dialysis patients and examined single measurements of NT-proBNP in time.
We measured NT-proBNP concentrations in 2990 incident hemodialysis patients to examine the risk of 90-day and 1-year mortality associated with baseline NT-proBNP concentrations. In addition, we calculated the change in concentrations after 3 months in a subset of 585 patients to examine the association between longitudinal changes in NT-proBNP and subsequent mortality.
Increasing quartiles of NT-proBNP were associated with a monotonic increase in 90-day [quartile 1, referent; from quartile 2 to quartile 4, hazard ratio (HR) 1.7-6.3, P < 0.001] and 1-year (quartile 1, referent; from quartile 2 to quartile 4, HR 1.7-4.9, P < 0.001) all-cause mortality. After multivariable adjustment, these associations remained robust. When examined using a multivariable fractional polynomial, increased NT-proBNP concentrations were associated with increased 90-day (HR per unit increase in log NT-proBNP 1.5, 95% CI 1.3-1.7) and 1-year (HR per unit increase in log NT-proBNP 1.4, 95% CI 1.3-1.5) all-cause mortality. In addition, patients with the greatest increase in NT-proBNP after 3 months of dialysis had a 2.4-fold higher risk of mortality than those with the greatest decrease in NT-proBNP.
NT-proBNP concentrations are independently associated with mortality in incident hemodialysis patients. Furthermore, the observation that longitudinal changes in NT-proBNP concentrations were associated with subsequent mortality suggests that monitoring serial NT-proBNP concentrations may represent a novel tool for assessing adequacy and guiding therapy in patients initiating hemodialysis.

Download full-text


Available from: Ishir Bhan, Jul 28, 2015
12 Reads
  • Source
    • "In patients with chronic kidney disease not requiring dialysis and without cardiac symptoms, NT-proBNP level elevation has been reported to reflect underlying coronary disease and left ventricular hypertrophy independent of renal function [23]. In addition, NT-proBNP concentrations were also independently associated with mortality in hemodialysis patients [24]. However, in patients undergoing noncardiac vascular surgery regardless of underlying cardiac disease, the prognostic value of NT-proBNP for cardiac outcomes was useful only in patients with GFR ≥ 30 ml/min/1.73 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Plasma levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) provide useful prognostic predictors in patients after cardiac surgery. However, predictive accuracy of NT-proBNP levels has varied significantly according to renal dysfunction. The purpose of this study was to assess whether preoperative NT-proBNP levels could be used as predictors of early postoperative outcomes on the basis of renal function in patients undergoing off-pump coronary artery bypass surgery (OPCAB). In 219 patients undergoing elective OPCAB, NT-proBNP and an estimated glomerular filtration rate (eGFR) were assessed preoperatively. All patients were divided into 3 groups according to tertiles of eGFR: the first (eGFR ≥ 90 ml/min/1.73 m(2)), the second (90 ml/min/1.73 m(2) > eGFR ≥ 72 ml/min/1.73 m(2)) and the third tertile group (eGFR < 72 ml/min/1.73 m(2)). End point was the composite of early postoperative complications defined as myocardial infarction, new onset atrial fibrillation, ventricular dysfunction, prolonged mechanical ventilator care (> 48 hr), prolonged ICU stay (≥ 3 days), and in hospital mortality. There was no difference in early postoperative complications among groups. A preoperative NT-proBNP level of 228 pg/ml and 302 pg/ml (sensitivity 70%, specificity 67%, P < 0.001 and sensitivity 73%, specificity 63%, P = 0.001, respectively) were optimal cut-off values predicting complicated early postoperative course in second and third tertile group, respectively. Preoperative NT-proBNP levels seem to be predictive of early postoperative complications in patients with eGFR < 90 ml/min/1.73 m(2) undergoing OPCAB.
    Korean journal of anesthesiology 07/2011; 61(1):35-41. DOI:10.4097/kjae.2011.61.1.35
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular events (CVE) are a major cause of morbidity and mortality in end-stage renal disease (ESRD) patients. These patients are often excluded from CV clinical trials, and the prognostic factors associated with CVE in patients with ESRD have not been fully explored. We investigated the role of BNP and NT-proBNP in predicting the outcome and prognostic value in hemodialysis with ESRD patients. Baseline NT-proBNP and BNP, indices of dialysis adequacy, and biochemical characteristics were assessed in 217 dialysis patients with ESRD who were followed prospectively for 2 years or until death. CVE included cardiovascular death, myocardial infarction, heart failure and stroke. Using multivariable Cox regression analysis, BNP and NT-proBNP remained predictive of cardiovascular mortality (BNP: hazard ratio 1.22, 95% confidence interval (CI) 1.21-11.04, p < 0.05; NT-proBNP hazard ratio 1.86, 95% CI 1.14-9.36, p < 0.05), fatal/nonfatal CHF (BNP: 1.35, 1.33-11.78, p < 0.05; NT-proBNP: 2.25, 1.54-12.68, p < 0.001) and fatal/nonfatal MI (BNP: 0.61, 2.38-19.53, p = 0.42; NT-proBNP: 1.90, 3.28-20.17, p < 0.001). NT-proBNP had better predictive value than BNP for mortality (area under the ROC curve (AUC) 0.83 vs. 0.61; p < 0.05). These data showed that BNP and NT-proBNP are very sensitive and specific predictors of CVE in dialysis patients.
    Nephron Clinical Practice 10/2008; 110(3):c178-84. DOI:10.1159/000167270 · 1.40 Impact Factor
  • Southern medical journal 12/2008; 101(11):1083. DOI:10.1097/SMJ.0b013e31818963f6 · 0.93 Impact Factor
Show more